Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic...

Area of Science:

• Pediatric Hematology Oncology
• Stem Cell Transplantation
• Leukemia Research

Background:

• Hematopoietic stem cell transplantation (HSCT) is a critical curative option for pediatric leukemia.
• Long-term survival and risk stratification are essential for optimizing post-transplant care in children with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

Purpose of the Study:

• To identify prognostic factors influencing leukemia-free survival (LFS) and overall survival (OS) in pediatric AML and ALL patients post-HSCT.
• To develop and validate risk scores for predicting long-term survival after related or unrelated donor transplantation.

Main Methods:

• Retrospective analysis of 790 AML and 1096 ALL patients transplanted between 2000-2010, surviving at least 1 year in remission.
• Evaluation of patient, disease, transplantation characteristics, and graft-versus-host disease (GVHD) to determine adverse prognostic factors.
• Development of risk scores for AML and ALL based on identified prognostic factors.

Main Results:

• For AML, risk score components include age, disease status, cytogenetic risk, and chronic GVHD. For ALL, risk score components include age and chronic GVHD.
• 10-year OS probabilities for AML: 94% (good risk), 87% (intermediate risk), 68% (poor risk).
• 10-year OS probabilities for ALL: 89% (good risk), 80% (poor risk).

Conclusions:

• Established risk scores effectively stratify long-term survival probabilities for pediatric AML and ALL patients post-HSCT.
• Early identification of high-risk children can guide interventions to mitigate late mortality.
• Prognostic factors beyond 4 years for AML and 3 years for ALL were not significant.